Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results
Meridian Funds, managed by ArrowMark Partners, released its “Meridian Growth Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here.
Agios Pharmaceuticals Inc. (AGIO)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 5,654,502 | $243,822,126 | +2% | 1.15% |
| 2. | Armistice Capital Steven Boyd | 2,079,151 | $89,652,991 | -30% | 1.12% |
| 3. | Biotechnology Value Fund / BVF Inc Mark Lampert | 1,190,107 | $51,317,414 | 1.43% | |
| 4. | Marshall Wace LLP Paul Marshall And Ian Wace | 1,133,735 | $48,886,654 | +308% | 0.06% |
| 5. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 1,044,261 | $45,028,534 | -41% | 1.35% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.00 | 40,322 | Officer, Director | 41,722 | 2019-11-13 | Filing | |
| $31.00 | 8,064 | Director | 97,567 | 2019-11-13 | Filing | |
| $31.00 | 403,225 | Large Shareholder | 1,777,824 | 2019-11-12 | Filing | |
| $83.44 | 200 | Director | 571 | 2018-03-16 | Filing | |
| $67.00 | 851,154 | Large Shareholder | 1,374,599 | 2018-01-23 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $49.03 | 2,542 | Officer | 20,158 | 2024-09-26 | Filing | |
| $42.75 | 11,091 | Officer, Director | 78,792 | 2024-08-08 | Filing | |
| $43.85 | 3,705 | Officer | 43,736 | 2024-07-01 | Filing | |
| $48.84 | 12,115 | Officer, Director | 67,192 | 2024-06-05 | Filing | |
| $44.39 | 1,362 | Officer | 1,524 | 2024-06-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,527,438 | $123,096,044 | 0% | |
| 2. | 4,962,237 | $110,509,016 | 0% | |
| 3. | 4,011,000 | $89,324,970 | 1.36% | |
| 4. | 2,625,685 | $58,474,005 | 0% | |
| 5. | 2,596,764 | $57,831,549 | 0.01% |
News See All
Top 10 Holdings of Caligan Partners
Founded in 2017, Caligan Partners is one of the most significant specialty hedge funds.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2024 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2024 Earnings Call Transcript August 1, 2024Agios Pharmaceuticals, Inc. misses on earnings expectations.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Agios’ First Quarter 2024 Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded at Agios’ request.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2023 Earnings Call Transcript
Operator: Good morning. And welcome to the Agios Fourth Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Agios Pharmaceuticals Incorporated quarter three 2023 earnings conference call.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q2 2023 Earnings Call Transcript
Operator: Good morning, and welcome to Agios’ Second Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2023 Earnings Call Transcript
Operator: Good morning, and welcome to Agios' First Quarter 2023 Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session at the end.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q4 2022 Earnings Call Transcript
Operator: Good morning, and welcome to Agios Fourth Quarter and Year-End 2022 Conference Call. At this time, all participants are in a listen-only mode.
Should I Avoid Agios Pharmaceuticals Inc (AGIO)?
With the second-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the third ...
Billionaire Hedge Funds
